WO2026133166 - METHOD FOR ASSESSING FUTURE ONSET OR PROGRESSION OF OCULAR HEALTH CONDITIONS
National phase entry is expected:
Publication Number
WO/2026/133166
Publication Date
25.06.2026
International Application No.
PCT/IB2025/063013
International Filing Date
16.12.2025
Title **
[English]
METHOD FOR ASSESSING FUTURE ONSET OR PROGRESSION OF OCULAR HEALTH CONDITIONS
[French]
PROCÉDÉ D'ÉVALUATION DE L'APPARITION OU DE LA PROGRESSION FUTURES D'ÉTATS DE SANTÉ OCULAIRE
Applicants **
MENICON CO., LTD.
Inventors
LAMRANI, Mouad
Priority Data
63/734,275
16.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
JPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2107 | |
| EPO | Filing, Examination, Granting | 12630 | |
| Japan | Filing, Examination, Granting | 1949 | |
| South Korea | Filing, Examination, Granting | 2265 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
23,691
Contact Us
Abstract[English]
Provided are methods of assessing future onset or progression of an ocular health condition in a subject, comprising obtaining a tear fluid sample from the subject; measuring, in the tear fluid sample, concentrations of a plurality of biomarkers of a biomarker panel, wherein the biomarker panel comprises at least two or more biomarkers from the group consisting of Nerve Growth Factor (NGF), Interleukin-8 (IL-8), Tumor Necrosis Factor-Alpha (TNF-α), and Interleukin- 13 (IL-13); comparing the measured biomarker concentrations to condition-specific signature criteria; and based on the comparison, identifying the subject as having proclivity to future onset or progression of: (i) Contact Lens Discomfort (CLD) when the measured NGF concentration and the measured IL-8 concentration meet a first condition-specific signature criterion, or (ii) Dry Eye Disease (DED) when the measured NGF concentration, the measured TNF-α concentration, and the measured IL-13 concentration meet a second condition-specific signature criterion.[French]
L'invention concerne des procédés d'évaluation de l'apparition ou de la progression futures d'un état de santé oculaire chez un sujet, comprenant l'obtention d'un échantillon de fluide lacrymal du sujet ; de mesure, dans l'échantillon de fluide lacrymal, des concentrations d'une pluralité de biomarqueurs d'un panel de biomarqueurs, le panel de biomarqueurs comprenant au moins deux biomarqueurs ou plus du groupe constitué du facteur de croissance nerveuse (NGF), de l'interleukine -8 (IL-8), du facteur de nécrose tumorale alpha (TNF-α), et de l'interleukine -13 (IL -13) ; de comparaison des concentrations de biomarqueurs mesurées à des critères de signature spécifiques à une condition ; et sur la base de la comparaison, d'identification du sujet comme ayant une aptitude à l'apparition ou à la progression futures de : (i) un inconfort de lentille de contact (CLD) lorsque la concentration de NGF mesurée et la concentration d'IL -8 mesurée satisfont un premier critère de signature spécifique à une condition, ou (ii) la maladie de l'œil sec (DED) lorsque la concentration de NGF mesurée, la concentration de TNF-α mesurée et la concentration d'IL-13 mesurée satisfont un second critère de signature spécifique à une condition.